Alligator Bioscience starts clinical phase I study with ATOR-1015
A first-in-class bispecific CTLA-4 antibodyLund, Sweden, December 11, 2018 – Alligator Bioscience AB (Nasdaq Stockholm: ATORX) today announces that regulatory approvals have been obtained for the first clinical study of ATOR-1015 and patient recruitment can now be initiated. ATOR-1015 is a wholly-owned drug candidate developed for tumor-directed immunotherapy. The phase I study is a first-in-human dose-escalation study in up to 53 patients with advanced solid tumor disease at five different clinics across Sweden and Denmark. The primary aim of the study will be to investigate the safety